Candel Therapeutics (CADL)
Develops viral immunotherapies for solid tumors through adenovirus and HSV platforms.
$11.62
vs last close−0.23 (−1.90%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 66.28% | 50.72M shares | |
|---|---|---|---|
| 146 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.85% | 6.77M shares | |
| 11 holders · as of Sep 11, 2026 | |||
| Other | ≈ 24.87% | 19.03M shares | |
| remainder | |||
76.52M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
146 holders · 50.72M shares · 42 new positions · 103 increased · 27 reduced · 16 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 10.99M | 14.36% | +3.5K | Aug 13, 2026 |
| RTW Investments, LP | 6.42M | 8.39% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 4.97M | 6.49% | +1.86M | Aug 7, 2026 |
| State Street Corp | 3.55M | 4.64% | +2.73M | Aug 7, 2026 |
| Acorn Capital Advisors, LLC | 3.50M | 4.57% | 0 | Aug 14, 2026 |
| Portolan Capital Management, LLC | 3.49M | 4.56% | +596.1K | Aug 14, 2026 |
| Saturn V Capital Management LLC | 3.30M | 4.32% | +407.1K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.69M | 3.52% | +231.3K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 9.30% | 3.92M | 13G | Feb 7, 2025 |
| RTW Investments, LP | 8.80% | 6.42M | 13G | May 15, 2026 |
| Paul B Manningincl. The Paul B. Manning Revocable Trust dated May 10, 2000, BKB Growth Investments, LLC | 7.90% | 5.79M | 13D | Mar 18, 2026 |
| BlackRock, Inc. | 6.60% | 4.83M | 13G | Jul 27, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 11, 2026 | Paul Peter Takdirector, officer: Chief Executive Officer | Sale | 59,379 | $10.46 | 113,321 |
| Sep 10, 2026 | Paul Peter Takdirector, officer: Chief Executive Officer | Sale | 220,866 | $11.50 | 172,700 |
| Aug 17, 2026 | Seshu Tyagarajanofficer: Chief Technology Officer | Sale | 7,000 | $12.00 | 76,865 |
| Jun 29, 2026 | Seshu Tyagarajanofficer: Chief Technology Officer | Sale | 7,000 | $10.02 | 83,865 |
| Jun 29, 2026 | Francesca Baroneofficer: Chief Scientific Officer | Sale | 23,447 | $10.06 | 77,362 |
| Feb 23, 2026 | Paul B. Manningdirector | Purchase | 550,458 | $5.45 | 2,763,527 |
House and Senate disclosures
Not reported.